Relief Therapeutics Aktie
| 3,02CHF | -0,12CHF | -3,67% |
WKN DE: A3EFB5 / ISIN: CH1251125998
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 31 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,27 |
Bilanz (in Mio. CHF) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 47 | 55 | 23 | 18 | 18 |
| Summe Anlagevermögen | 31 | 197 | 166 | 58 | 35 |
| Summe Aktiva | 78 | 252 | 189 | 76 | 53 |
Bilanz (in Mio. CHF) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 11 | 70 | 43 | 24 | 17 |
| Summe Eigenkapital | 67 | 182 | 145 | 52 | 37 |
| Summe Passiva | 78 | 252 | 189 | 76 | 53 |
Adresse
| Avenue de Sécheron 15, 1202 Geneva | |
| Telefon | +41 (22) 545-11-16 |
| Internet | http://www.relieftherapeutics.com |
Management
|
Giorgio Reiner
Chief Scientific Officer |
|
Gregory A. Van Beek
Director |
|
Jeremy Meinen
Chief Financial Officer & Treasurer |
|
Paolo Galfetti
Chief Business Officer |
|
Peter Egon de Svastich
Director |
|
Raghuram Selvaraju
Chairman |
|
Tommy Elzinga
Director |
|
Vincenzo Gallo
Head-Legal & Compliance |